Literature DB >> 16137750

Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.

Amy Finch1, Patricia Shaw, Barry Rosen, Joan Murphy, Steven A Narod, Terence J Colgan.   

Abstract

OBJECTIVE: To estimate the likelihood of occult cancer diagnosis at prophylactic oophorectomy in BRCA1 and BRCA2 carriers in different age groups and to determine the histopathology of these lesions.
METHODS: We describe a series of 159 female BRCA1 or BRCA2 carriers who underwent prophylactic oophorectomy at the University Health Network, Toronto from January 1, 1992 to June 30, 2004.
RESULTS: Seven (4.4%) occult cancers were detected at pathologic examination. None of the 159 subjects had clinical signs or symptoms of ovarian carcinoma prior to, or at the time of, surgery. Only two cancers were grossly visible at surgery. There were 94 BRCA1 carriers, of whom six were found to have an occult cancer (6.4%). In contrast, only one of the 65 BRCA2 carriers was found to have an occult cancer (1.5%). Three of the seven cases of occult malignancy involved the fallopian tube and not the ovaries.
CONCLUSION: Approximately 6% of BRCA1 carriers and 2% of BRCA2 carriers who undergo prophylactic salpingo-oophorectomy will be found to have occult carcinomas if the ovaries and tubes are rigorously examined. A significant proportion of these appear to originate in the fallopian tube. No cancers were detected among women who had the operation at age 39 or younger.

Entities:  

Mesh:

Year:  2005        PMID: 16137750     DOI: 10.1016/j.ygyno.2005.06.065

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  103 in total

1.  Screening for ovarian cancer: imaging challenges and opportunities for improvement.

Authors:  K B Mathieu; D G Bedi; S L Thrower; A Qayyum; R C Bast
Journal:  Ultrasound Obstet Gynecol       Date:  2018-03       Impact factor: 7.299

2.  Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases.

Authors:  Daichi Maeda; Satoshi Ota; Yutaka Takazawa; Kenichi Ohashi; Masaya Mori; Tetsuo Imamura; Shunsuke Nakagawa; Tetsu Yano; Yuji Taketani; Masashi Fukayama
Journal:  Virchows Arch       Date:  2010-09-25       Impact factor: 4.064

3.  Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations.

Authors:  James R Conner; Emily Meserve; Ellen Pizer; Judy Garber; Michael Roh; Nicole Urban; Charles Drescher; Bradley J Quade; Michael Muto; Brooke E Howitt; Mark D Pearlman; Ross S Berkowitz; Neil Horowitz; Christopher P Crum; Colleen Feltmate
Journal:  Gynecol Oncol       Date:  2013-12-12       Impact factor: 5.482

Review 4.  The mammalian ovary from genesis to revelation.

Authors:  Mark A Edson; Ankur K Nagaraja; Martin M Matzuk
Journal:  Endocr Rev       Date:  2009-09-23       Impact factor: 19.871

5.  The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube.

Authors:  Wa Xian; Alexander Miron; Michael Roh; Dana R Semmel; Yosuf Yassin; Judy Garber; Esther Oliva; Annekathryn Goodman; Karishma Mehra; Ross S Berkowitz; Christopher P Crum; Bradley J Quade
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

6.  Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers.

Authors:  Laura L Holman; Sue Friedman; Molly S Daniels; Charlotte C Sun; Karen H Lu
Journal:  Gynecol Oncol       Date:  2014-02-28       Impact factor: 5.482

7.  Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases.

Authors:  Xiying Shang; Xinjian Lin; Edwin Alvarez; Gerald Manorek; Stephen B Howell
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

8.  Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Joanne Kotsopoulos; Jan Lubinski; Jacek Gronwald; Cezary Cybulski; Rochelle Demsky; Susan L Neuhausen; Charmaine Kim-Sing; Nadine Tung; Susan Friedman; Leigha Senter; Jeffrey Weitzel; Beth Karlan; Pal Moller; Ping Sun; Steven A Narod
Journal:  Int J Cancer       Date:  2014-12-18       Impact factor: 7.396

Review 9.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

10.  A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.

Authors:  Cheryl A Sherman-Baust; Elisabetta Kuhn; Blanca L Valle; Ie-Ming Shih; Robert J Kurman; Tian-Li Wang; Tomokazu Amano; Minoru S H Ko; Ichiro Miyoshi; Yoshihiko Araki; Elin Lehrmann; Yongqing Zhang; Kevin G Becker; Patrice J Morin
Journal:  J Pathol       Date:  2014-07       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.